Connor Clark & Lunn Investment Management Ltd. Trims Position in Enovis Co. (NYSE:ENOV)

Connor Clark & Lunn Investment Management Ltd. lowered its position in Enovis Co. (NYSE:ENOV - Free Report) by 26.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,524 shares of the company's stock after selling 32,916 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.16% of Enovis worth $4,104,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Amalgamated Bank grew its position in shares of Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company's stock worth $1,136,000 after buying an additional 264 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after purchasing an additional 300 shares during the period. Arizona State Retirement System raised its holdings in shares of Enovis by 2.6% in the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company's stock valued at $711,000 after purchasing an additional 414 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the period. Finally, New York State Teachers Retirement System boosted its stake in shares of Enovis by 3.5% during the fourth quarter. New York State Teachers Retirement System now owns 13,538 shares of the company's stock valued at $594,000 after purchasing an additional 457 shares in the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Enovis Stock Down 0.1 %

NYSE ENOV traded down $0.05 during trading on Thursday, hitting $39.38. The company's stock had a trading volume of 568,330 shares, compared to its average volume of 666,684. Enovis Co. has a fifty-two week low of $35.14 and a fifty-two week high of $62.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company has a market cap of $2.24 billion, a PE ratio of -17.98 and a beta of 2.05. The business's 50 day simple moving average is $42.97 and its 200-day simple moving average is $43.59.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reduced their price target on Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.